


Product Name	: Nazartinib
Synonyms	: EGF816; EGF-816; EGF 816; NVS-816
Cat No.	: M17328
CAS Number	: 1508250-71-2
Molecular Formula	: C ₂₆ H ₃₁ ClN ₆ O ₂
Formula Weight	: 495.02
Chemical Name	: (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide
Description	Nazartinib, also known as EGF816 and NVS-816, is an orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.
Pathway	: Autophagy
Target	: CCR
Receptor	: EGFR (mutant)
Solubility	: DMSO : ≥ 242 mg/mL; 488.87 mM
SMILES	: <chem>Cc1nccc(c1)C(=O)Nc1nc2c(n1[C@@H]1CCCCN(C1)C(=O)/C=C/CN(C)C)c(ccc2)Cl</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:



1. G rald Lelais, et al J. Med. Chem., 2016, 59 (14), pp 6671–6689